Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$3.05B |
| 2 |
Coupang
CPNG
|
+$1.02B |
| 3 |
Trade Desk
TTD
|
+$941M |
| 4 |
Affirm
AFRM
|
+$795M |
| 5 |
Bilibili
BILI
|
+$729M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$8.35B |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$1.34B |
| 3 |
NIO
NIO
|
+$810M |
| 4 |
Meta Platforms (Facebook)
META
|
+$804M |
| 5 |
Amazon
AMZN
|
+$792M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 31.68% |
| 2 | Healthcare | 19.13% |
| 3 | Technology | 16.8% |
| 4 | Communication Services | 14.58% |
| 5 | Financials | 5.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
HEICO Corp
HEI
$51.4B
| $20.8M | 0.01% |
165,121
+8,073
| +5% | +$1.04M |
|
227
BridgeBio Pharma
BBIO
$16.5B
| $19.3M | 0.01% |
312,645
+194,113
| +164% | +$12.7M |
|
|
NCNA
228
NuCana
NCNA
$6.12M
| $18.3M | 0.01% |
732
+68
| +10% | +$1.89M |
|
229
Align Technology
ALGN
$12.3B
| $15.9M | 0.01% |
29,346
| – | – |
|
|
MASI
230
DELISTED
Masimo
MASI
| $15.6M | 0.01% |
68,098
+36,731
| +117% | +$9.23M |
|
231
Visa
V
$677B
| $15.3M | 0.01% |
72,337
| – | – |
|
232
Cooper Companies
COO
$14.5B
| $13.7M | 0.01% |
142,800
| – | – |
|
233
Invesco Senior Income Trust
VVR
$454M
| $13.4M | 0.01% |
3,195,695
| – | – |
|
234
Ascendis Pharma A/S
ASND
$16.8B
| $13.2M | 0.01% |
102,294
+55,139
| +117% | +$8.38M |
|
|
KDNY
235
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $13.1M | 0.01% |
845,485
+801
| +0.1% | +$13.1K |
|
|
BNFT
236
DELISTED
Benefitfocus, Inc.
BNFT
| $13M | 0.01% |
944,514
-3,098
| -0.3% | -$44.6K |
|
237
Health Catalyst
HCAT
$128M
| $12.3M | 0.01% |
262,830
+140,777
| +115% | +$6.82M |
|
238
Sherwin-Williams
SHW
$89.8B
| $12.3M | 0.01% |
49,893
| – | – |
|
239
Ionis Pharmaceuticals
IONS
$9.4B
| $10.7M | 0.01% |
237,959
+111,741
| +89% | +$6.23M |
|
240
Verisk Analytics
VRSK
$25B
| $10.2M | 0.01% |
57,521
| – | – |
|
241
BlackRock Floating Rate Income Trust
BGT
$325M
| $9.81M | 0.01% |
784,230
| – | – |
|
242
HUTCHMED
HCM
$2.17B
| $9.13M | 0.01% |
323,153
+29,130
| +10% | +$929K |
|
243
TJX Companies
TJX
$178B
| $8.73M | ﹤0.01% |
132,048
-83,202
| -39% | -$5.57M |
|
244
British American Tobacco
BTI
$128B
| $8.48M | ﹤0.01% |
218,797
-441
| -0.2% | -$16.6K |
|
245
Veeva Systems
VEEV
$37.4B
| $7.9M | ﹤0.01% |
30,244
+16,220
| +116% | +$4.52M |
|
246
Fortive
FTV
$18.6B
| $7.7M | ﹤0.01% |
144,725
-209
| -0.1% | -$10.8K |
|
247
American Well
AMWL
$230M
| $6.93M | ﹤0.01% |
19,964
+10,629
| +114% | +$5.76M |
|
248
StoneCo
STNE
$2.58B
| $6.37M | ﹤0.01% |
104,056
-24,456
| -19% | -$1.91M |
|
249
Relay Therapeutics
RLAY
$4.33B
| $5.92M | ﹤0.01% |
171,286
+91,354
| +114% | +$3.96M |
|
|
KLDO
250
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
| $5.33M | ﹤0.01% |
657,391
+217,391
| +49% | +$2.37M |
|
Similar funds
Baillie Gifford & Co's Q1 2021 Portfolio in Review
As of Q1 2021, Baillie Gifford & Co held 469 positions worth $179B, down 0.52% from $180B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Baillie Gifford & Co's Q1 2021 filing shows 39 new, 260 increased, 115 reduced and 23 closed positions. Its largest new stake was Coupang: 22,054,023 shares worth $1.09B. The largest sale was Tesla, an estimated $8.35B.
By sector, the portfolio is most concentrated in Consumer Discretionary at 32% of assets, down from 38% a quarter earlier, followed by Healthcare and Technology.
- Baillie Gifford & Co's largest Q1 2021 buy was Coupang: 22,054,023 shares worth $1.09B.
- Baillie Gifford & Co added most to Moderna in Q1 2021, an estimated $3.05B increase.
- Baillie Gifford & Co's biggest Q1 2021 reduction was Tesla, cutting an estimated $8.35B.
- Baillie Gifford & Co fully exited Stellantis in Q1 2021, selling an estimated $533M.
- Baillie Gifford & Co's ten largest holdings make up 37% of its $179B portfolio in Q1 2021.
- Baillie Gifford & Co opened 39 new positions and closed 23 in Q1 2021.
- Baillie Gifford & Co's portfolio value fell 0.52% quarter-over-quarter to $179B.
Based on Baillie Gifford & Co's 13F filing for Q1 2021, filed 6 May 2021.